迈博药业-B2024中期报告

24511374648495152547579 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands G79225300 8318A 183171712-1716 97927 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 50037 1 123 2181 www.mabpharm.cn 913 •CMAB009®CMAB009®EGFRS20240025FOLFIRIRAS/BRAFmCRCCMAB009PCTPCTPCT/CN2016/070024(CHO) CMAB009®CMAB009®CMAB009®CMAB009®mCRCEGFRCMAB009®CMAB009® 50EGFR2%EGFRCMAB009®CMAB009®CMAB009® •CMAB008®S202100251234656CMAB008®GMPCMAB008® CMAB008®1,000688136CMAB008®CMAB008®47%CMAB008®MIS-CCMAB008® CMAB008®CMAB008®CMAB008®GMPPIC/SGMPCMAB008® •CMAB007®S2023003075mgS20230031150mgEIgECMAB007®H112CMAB007®IIIIgECMAB007®CMAB007® CMAB007®CMAB007®CMAB007®GPOCMAB007®CMAB007®18778% CMAB015CMAB015IIIICMAB807/CMAB807XIIINDACMAB017EGFRCMAB017CMAB022 203863 7,500GMPGMP40,000CDMO PIC/SGMP ®CMAB009 CMAB009®EGFRFOLFIRImCRCCMAB009PCTPCTPCT/CN2016/070024CHO CMAB009® CMAB009®FOLFIRImCRCCMAB009®mCRCEGFRCMAB009®CMAB009® 50EGFR2%EGFRCMAB009®CMAB009®CMAB009® ®CMAB008 CMAB008®TNFS20210025 (i)(ii)(iii)(iv)6(v)(vi) CMAB008®CMAB008®CHOTNFTNFCMAB008®TNFTNFCMAB008®CMAB008® CMAB008®CMAB008®1,000(IBD) CMAB008® CMAB008®47%CMAB008®MIS-CCMAB008®GMPPIC/SGMPCMAB008® ®CMAB007 CMAB007®IgEIgECMAB007®IgEIgEIgECMAB007®4824CMAB007®CMAB007®CMAB007® CMAB007®S2023003075mgS20230031150mgIgENDACMAB007®H112CXSL230037775mgCXSL2300378150mgCMAB007®NDA CMAB007®CMAB007®CMAB007®CMAB007®CMAB007®GPOAB50CMAB007®18CMAB007®CMAB007®778% CMAB807/CMAB807XRANKLBG2IgG2RANKLCMAB807/CMAB807XRANKLRANKRANKLRANK RANKLRANKLRANKRANKCMAB807/CMAB807XRANKLRANK CMAB807/CMAB807XIIINDACMAB807/CMAB807X CMAB017EGFRCMAB017G1IgG1FcCMAB017CMAB017CMAB017CMAB017CMAB01724-72CMAB017I CMAB015secukinumabIgG117AIL-17A17IL-17IL-17ACMAB015IL-17ACMAB015IIIICMAB015NDA CMAB819CMAB819ICMAB819CMAB819 CMAB022®stelara®ustekinumab12IL-1223IL-23IL-12IL-23P40IL-12R1IL-12IL-23(FDA)UNITI-1UNITI-2IM-UNITITNFCMAB022IIII CMAB023TSLPIgG2-lambdaTEZSPIRETezepelumabTSLPTSLPTSLPCMAB023 CMAB016®Dupixent®dupilumabG4IgG4CMAB0164IL-4IL-413IL-13FDABOREASNOTUS52(COPD)30%34%52FDA6COPDCMAB016 CMAB008CMAB007CMAB009CMAB807/CMAB807XNDAGMP 30,000(i)3×1,500(ii)400(iii)100CMAB008CMAB007CMAB009GMPPIC/SGMP 100,746(i)7,50018,000(ii)GMP40,000 CMAB008®GMPPIC/SCMAB008GMPCMAB008 (i)(ii) GMPGMP PIC/S CMAB008CMAB007CMAB009CMAB807/CMAB807XCMAB015 44.0146.4%108.5 6.2127.9%14.1 3.764.7%1.3 2.780.6%0.5 59.55.4%56.3 47.228.6%60.7 4.520.5%5.4 19.4230.3%64.2 49.8193.822.5 49.8 288100,74633.950,835110.830.018197.5100.0 412,4084,124,080,000 87.8%12.2%80.2%19.8% 100%87.8%80.2% 1.11.10.80.7 1,144.5 29756241 (1)21 212151 XV(i)XV78(ii)352(iii)C3 (1)4,124,080,000 (2) XVXV78352 336 (1)Asia Mabtech49.95%4.05%Asia Mabtech100%Asia MabtechAsia Pacific Immunotech VentureAsia Pacific Immunotech VentureXV167,025,000Asia Mabtech2,059,975,000(2)CDH PE18.00%CDH PECDH FundCDH FundCDH PECDH FundCDH VCDH VChina Diamond V80%ChinaDiamond VChina Diamond100%(3)FH InvestmentLink Best Capital LimitedLink Best Capital Limited 336 6283,512,50083,512,500282874,383,2581.80% 20% 1.50 13.51B(1) 2410 13.1313.19 TNFCMAB008®(i)(ii)(iii)(iv)6(v)(vi) Ernst & Young27/F, One Taikoo Place979 King’s RoadQuarry Bay, Hong Kong 4874343434 2410 34 1. 190 Elgin Avenue, George Town, Grand Cayman KY1-9008,Cayman IslandsG79 Asia Mabtech Limited 2. 34 3. 161177 (a)1616 3. (b)12 (c)77 4. 8 10%7,075,000 5. 5. 6. 7. 8. 9. 10. 11. 12. 13. 2,142,0002,117,0008,897,0007,319,000 296,000 14. a.100,746 b. 17. 60 18. 19. 20. 21. (a) a.b.45,000,0003.7%22,500,000 21. 21. (b) 60 a.CMAB80766,038,00047,170,000 21. 22. TNFTNFcachexinCD4+ DNA